ストックスクリーナーアプリを入手
1.61
6.94%
-0.12
アフターアワーズ：
1.64
0.03
+1.86%
前日終値:
$1.73
開ける：
$1.73
24時間の取引高:
1.72M
Relative Volume:
0.91
時価総額：
$212.57M
収益：
$79,600
当期純損益:
$-48.26M
株価収益率:
-3.271
EPS:
-0.4922
ネットキャッシュフロー:
$-28.24M
1週間 パフォーマンス:
-20.69%
1か月 パフォーマンス:
-12.02%
6か月 パフォーマンス:
+0.63%
1年 パフォーマンス:
-19.90%
1日の値動き範囲:
$1.57
$1.77
1週間の範囲:
$1.57
$2.04
52週間の値動き範囲:
$1.33
$2.26
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
(302) 295-3800
住所
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.61 | 228.42M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2026-01-21 | 開始されました | BofA Securities | Buy |
| 2025-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
IKT Technical Analysis | Trend, Signals & Chart Patterns | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors - TipRanks
Is Inhibikase Therapeutics (IKT) Fairly Valued After Q1 2026 EPS - GuruFocus
Inhibikase Advances PAH Drug with Global Phase 3 Trial Launch - BriefGlance
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum - ChartMill
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase (NASDAQ: IKT) deepens Q1 loss as pivotal PAH trial advances globally - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INHIBIKASE THERAPEUTICS ($IKT) Releases Q1 2026 Earnings - Quiver Quantitative
Inhibikase (NASDAQ: IKT) advances IMPROVE-PAH as Q1 2026 loss widens - Stock Titan
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics 宣佈2026年第一季度財務業績並重點介紹近期活動 - Moomoo
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension - TipRanks
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
What XXxs fundamentals reveal about its future (Rallies) 2026-05-08AI Powered Stock Picks - newser.com
Inhibikase Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - newser.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Strategic Review - newser.com
[DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
[ARS] Inhibikase Therapeutics, Inc. SEC Filing - Stock Titan
Inhibikase Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossSpecial Dividend - newser.com
Is Inhibikase Therapeutics (IKT) stock reversing trend | Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossConsensus Beat - newser.com
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
Inhibikase Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
What does insider activity suggest for Inhibikase Therapeutics (IKT) Stock | Price at $1.76, Up 3.53%Fibonacci Analysis - newser.com
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
2.53%
大文字化:
|
ボリューム (24 時間):